|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tummala KS, Gomes AL, Yilmaz M, Graña O,
Bakiri L, Ruppen I, Ximénez-Embún P, Sheshappanavar V,
Rodriguez-Justo M, Pisano DG, et al: Inhibition of de novo NAD(+)
synthesis by oncogenic URI causes liver tumorigenesis through DNA
damage. Cancer Cell. 26:826–839. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lee SA, Park KH and Lee JW: Modulation of
signaling between TM4SF5 and integrins in tumor microenvironment.
Front Biosci (Landmark Ed). 16:1752–1758. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wright MD, Ni J and Rudy GB: The L6
membrane proteins-a new four-transmembrane superfamily. Protein
Sci. 9:1594–1600. 2009. View Article : Google Scholar
|
|
5
|
Lee SA, Ryu HW, Kim YM, Choi S, Lee MJ,
Kwak TK, Kim HJ, Cho M, Park KH and Lee JW: Blockade of
four-transmembrane L6 family member 5 (TM4SF5)-mediated
tumorigenicity in hepatocytes by a synthetic chalcone derivative.
Hepatology. 49:1316–1325. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wu YB, Huang YS, Xu YP, Sun YF, Yu DL,
Zhang XQ, Long X, Zhu SQ, Zhou JL and Xu JJ: A high level of TM4SF5
is associated with human esophageal cancer progression and poor
patient survival. Dig Dis Sci. 58:2623–2633. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Park BK, Park JY, Kim TH, Kim D, Wu G,
Gautam A, Maharjan S, Lee SI, Lee Y, Kwon HJ and Choi KC:
Production of an anti-TM4SF5 monoclonal antibody and its
application in the detection of TM4SF5 as a possible marker of a
poor prognosis in colorectal cancer. Int J Oncol. 53:275–285.
2018.PubMed/NCBI
|
|
8
|
Lee D and Lee JW: Self-renewal and
circulating capacities of metastatic hepatocarcinoma cells required
for collaboration between TM4SF5 and CD44. BMB Rep. 48:127–128.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Amicone L and Marchetti A:
Microenvironment and tumor cells: Two targets for new molecular
therapies of hepatocellular carcinoma. Transl Gastroenterol
Hepatol. 3:242018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dutta R and Mahato RI: Recent advances in
hepatocellular carcinoma therapy. Pharmacol Ther. 173:106–117.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Reeves HL, Zaki MY and Day CP:
Hepatocellular carcinoma in obesity, type 2 diabetes, and NAFLD.
Dig Dis Sci. 61:1234–1245. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Trojan J, Zangos S and Schnitzbauer AA:
Diagnositics and treatment of hepatocellular carcinoma in 2016:
Standrads and developments. Visc Med. 32:116–120. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lee SA, Lee SY, Cho IH, Oh MA, Kang ES,
Kim YB, Seo WD, Choi S, Nam JO, Tamamori-Adachi M, et al:
Tetraspanin TM4SF5 mediates loss of contact inhibition through
epithelial- mesenchymal transition in human hepatocarcinoma. J Clin
Invest. 118:1354–1366. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Besson A, Gurian-West M, Schmidt A, Hall A
and Roberts JM: p27Kip1 modulates cell migration through the
regulation of RhoA activation. Genes Dev. 18:862–876. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kim H, Kang M, Lee SA, Kwak TK, Jung O,
Lee HJ, Kim SH and Lee JW: TM4SF5 accelerates G1/S phase
progression via cytosolic p27Kip1 expression and RhoA activity.
Biochim Biophys Acta. 1803:975–982. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hanahan D and Weinberg RA: The hallmarks
of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sadej R, Romanska H, Baldwin G,
Gkirtzimanaki K, Novitskaya V, Filer AD, Krcova Z, Kusinska R,
Ehrmann J, Buckley CD, et al: CD151 regulates tumorigenesis by
modulating the communication between tumor cells and endothelium.
Mol Cancer Res. 7:787–798. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Choi S, Lee S-A, Kwak TK, Kim HJ, Lee MJ,
Ye SK, Kim SH, Kim S and Lee JW: Cooperation between integrin
alpha5 and teraspan TM4SF5 regulates VEGF-mediated angiogenic
activity. Blood. 113:1845–1855. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lee D, Na J, Ryu J, Kim HJ, Nam SH, Kang
M, Jung JW, Lee MS, Song HE, Choi J, et al: Interaction of
tetraspan(in) TM4SF5 with CD44 promotes self-renewal and
circulating capacities of hepatocarcinoma cells. Hepatology.
61:1978–1997. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kim H, Jung O, Kang M, Lee MS, Jeong D,
Ryu J, Ko Y, Choi YJ and Lee JW: JNK signaling activity regulates
cell-cell adhesions via TM4SF5-mediated p27(Kip1) phosphorylation.
Cancer Lett. 314:198–205. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ryu J, Kang M, Lee MS, Kim HJ, Nam SH,
Song HE, Lee D and Lee JW: Cross talk between the TM4SF5/focal
adhesion kinase and the interleukin-6/STAT3 pathways promotes
immune escape of human liver cancer cells. Mol Cell Biol.
34:2946–2960. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
